Traditional brain imaging methods include magnetic resonance imaging (MRI) and computed tomography (CT) scans, as well as emerging imaging technologies such as positron emission tomography (PET) and PET-MRI or PET-CT.
However, magnetic resonance imaging (MRI) is a well-established technology with a long history of use, advanced MRI methods such as diffusion tensor imaging (DTI), diffusion-weighted imaging (DWI), sensitivity-weighted imaging (SWI), and dynamic. Sensitivity contrast (DSC) imaging technology is becoming more widely used in North America and Europe.
In terms of quantitative analysis, brain imaging software is a helpful complement to the scanned images produced by these methods.
Quantitative insights into anatomy, biomarkers, and other minor abnormalities in the brain can help physicians more accurately diagnose neurological disorders.
Factors such as the increasing frequency of neurological illnesses, the evolving AI integration in medical imaging, and the growing need for secure and non-invasive medical imaging technology are driving the market for brain disease procedures and software.
According to BIS research, Global brain disease procedures and software market It was valued at $ 13.05 billion in 2021 and is projected to reach $ 21.86 billion by the end of 2031. During the forecast period from 2022 to 2031, the market is expected to grow at a CAGR of 5.31%.
Get a free sample copy of this report here
What is positron emission tomography (PET)?
PET stands for Positron Emission Tomography, a nuclear drug process that evaluates the metabolic activity of cells in body tissues. PET is a type of imaging that combines nuclear medicine and biochemistry.
PET is often used to monitor biochemical changes in the body of people with brain or heart disease, as well as cancer, such as heart muscle metabolism (the process by which cells convert food into energy after it has been digested and absorbed).
PET differs from other nuclear drug tests in that it identifies metabolism in biological tissues, whereas other nuclear drug tests measure the amount of radioactive chemicals collected in a specific region to evaluate tissue function.
PET operations were conducted primarily at specialized PET facilities as the equipment needed to manufacture radiopharmaceuticals, such as cyclotrons and a radiochemistry lab, as well as PET scanners, had to be accessible.
Now, as radiopharmaceuticals are manufactured in different locations and delivered to PET facilities, only a scanner is needed to complete a PET scan.
PET-computed tomography (CT) scan
PET scan is a type of diagnostic technology that can be used to diagnose and treat cancer. It is possible to use it simultaneously with a CT scan. If so, doctors call it a PET-CT scan. Although it is sometimes referred to as PET scan.
In some malignancies, PET-CT scanning can help detect cancer and estimate its stage. The term “stage” refers to the location of the cancer and whether it has spread.
Doctors will also discover the stage of the cancer and how it is affecting your body’s processes. Knowing the stage of your cancer can help you and your doctor decide on the best treatment option. It can also help your healthcare provider predict the overall situation.
Is PET-CT scan safe?
During PET-CT scans, there is a risk of exposure to radiation. This type of scan employs X-rays, PET scans, or a combination of the two components. Less radiation is emitted when examining a small body area. A CT scan without dyes alone gives the same results as visual aids.
The benefits of these tests outweigh the risks. Throughout all these experiments, people will be exposed to small amounts of radiation. There is no evidence that these small doses of radiation cause damage.
There may be a smaller, higher risk in the future for children or other people who need numerous PET scans, CT scans and X-rays. Doctors may use low-dose scans or limit the number of locations that must be examined.
PET-Magnetic Resonance Imaging (MRI)
PET – MRI is a hybrid imaging technique that combines MRI soft tissue morphological imaging and PET functional imaging.
Oncology, Cardiology, Neurology and Neuroscience are the primary clinical domains of PET-MRI at the moment. Currently, research is being done to better understand the advantages of the novel PET-MRI diagnostic method.
The method combines the exceptional sensitivity of PET imaging and the excellent structural and functional properties of tissue MRI with tracking of individually labeled cell types or cell receptors.
Clinical and pre-clinical combined PET-MR systems are available from a variety of organizations; Clinical systems are supplied from Philips, Siemens and GE.
The merger of the two strategies is communicated in different ways. Some designs are different machines with a bed in the same room that allow a patient to move from one scanner to another.
Fully integrated systems are technically the most difficult to implement, but they offer the greatest advantage in terms of the ability to handle simultaneously with fully aligned acquisitions.
The need for neuroimaging services decreased but was offset by the need for pulmonary imaging and COVID-19 therapy testing.
As a result, most hospitals have redirected funds to save the equipment needed to fight COVID-19, which seems more complicated.
The future of PET, PET-CT, and PET-MRI imaging methods may have a higher share of the global brain disease system and software market.
Imaging methods that integrate the capabilities of many methods, such as PET and MRI, will probably help diagnose more specific diseases.
Interested in what innovative technology is gaining traction in your industry? BIS Research provides the most up-to-date market research and research. Contact us at email@example.com to learn more.